By Matt Grossman

 

AbbVie Inc. said Tuesday that its treatment for atopic dermatitis met the main goals of a Phase 3 study.

The treatment, Rinvoq, is an orally administered JAK inhibitor that was combined with topical corticosteroids in the study. Rinvoq led to significantly better skin results for patients in the 16-week trial than topical corticosteroids given along with a placebo, AbbVie said.

The results included measurements of skin clearance and itching. Two-thirds to three-quarters of patients receiving the treatment met a skin-clearance benchmark, compared with 11% of those who received a placebo.

The rate of serious adverse events--in the low single-digit range--was comparable to the level of such events in patients who only received a placebo, AbbVie said.

Atopic dermatitis, an inflammatory condition, causes itching and cracked, scaly skin.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

July 28, 2020 09:14 ET (13:14 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more AbbVie Charts.